>

WEBINARS

RSS
>

MEETINGS / EVENTS

RSS
>

FDA MEDWATCH ALERTS

RSS

May 20, 2013

All Sterile Drug Products Made and Distributed By NuVision Pharmacy Dallas Facility: Recall - Lack Of Sterility Assurance

Summary:

All Sterile Drug Products Made and Distributed By NuVision Pharmacy Dallas Facility

May 14, 2013

Zolpidem Containing Products: Drug Safety Communication - FDA Requires Lower Recommended Doses

Summary:

Zolpidem Containing Products Drug Safety Communication

May 09, 2013

The Compounding Shop: FDA News Release - Lack of Sterility Assurance of Drug Products

Summary:

The Compounding Shop FDA News Release Lack of Sterility

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Anesthesiology Continuing Education (ACE) Program

SKU: 30702-13CE

... Read more »

Single Copies, Member Price: $360

Dexamethasone Sodium Phosphate Injection, 4 mg/mL, 30 mL Multiple Dose Vial: Recall due to Particulates in Product

Friday, December 24, 2010

ISSUE: American Regent and FDA notified healthcare professionals of the nationwide recall of specific lots of Dexamethasone Sodium Phosphate Injection, USP 4 mg/mL, 30 mL Multiple Dose Vial because some vials of these lots either contain particulates or have the potential to form particulates prior to their respective expiration dates.

BACKGROUND: This voluntary recall was initiated December 20, 2010 because some vials of these lots either contain particulates or have the potential to form particulates prior to their respective expiration dates. American Regent is undertaking this recall in consideration of the potential for safety issues if these lots of product are administered to patients.

RECOMMENDATION: The recalled lots are listed in the firm's press release below. Hospitals, infusion centers, clinics and other healthcare facilities should not use the drug product with these lot numbers for patient care and should immediately quarantine any product for return. As stated in the Dexamethasone Sodium Phosphate Injection, USP Product Package Insert, “Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.”

[12/24/2010 - Firm Press Release - American Regent]

« Back to FDA Alerts and Recalls